A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-Part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-KHK in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-KHK in Obese Patients With Type 2 Diabetes Mellitus (T2DM)
Sponsor: Alnylam Pharmaceuticals
Terminated
Business reasons (not safety related)
Other terminated trials from Alnylam Pharmaceuticals
Other Type 2 Diabetes Mellitus (T2DM) trials with similar outcome
Listed as NCT05761301, this PHASE1/PHASE2 trial focuses on Type 2 Diabetes Mellitus (T2DM) and remains terminated or withdrawn. Sponsored by Alnylam Pharmaceuticals, it has been updated 21 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 16 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alnylam Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .